
FDA to Review Nogapendekin Alfa in Bladder Cancer and Lymphopenia
ImmunityBio has submitted a supplemental biologics license application (sBLA) to the FDA seeking approval for nogapendekin alfa inbakicept (Anktiva) plus Bacillus Calmette-Guérin (BCG) in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), …